NICE - Endorsed Technology Appraisals 2008/2009

Technology Appraisals

Fully Endorsed

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA103 - Psoriasis - Efalizumab and Etarnercept

• Note: this revised circular supersedes circular HSC (SQSD) (NICE) 11/07 TA103/07 originally issued in April 2007. NICE has suspended the use of Efalizumab for the treatment of psoriasis due to a safety alert from the EMEA - HSC (SQSD) (NICE) 21/09

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA123 - Varenicline for Smoking Cessation - HSC (SQSD) (NICE) 21/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA124 - Pemetrexed for Non-small Cell Lung Cancer - HSC (SQSD) (NICE) 22/08

• NOTE: Pemetrexed has now been recommended for the first-line treatment of non-small-cell lung cancer (NICE TA181). NICE Technology Appraisal TA124 applies to patients who have had prior chemotherapy. NICE Technology Appraisal TA181 was endorsed by DoH in September 2010: HSC (SQSD) (NICE) 19/10

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA126 - Rituximab for Rheumatoid Arthritis (refractory

• This guidance has been replaced by NICE TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor, which was endorsed by DoH in November 2011

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA130 - Adalimumab, Etanercept and Infliximab for the treatment of rheumatoid arthritis

• This guidance has been replaced or partially updated by TA375 - Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed, endorsed by the DoH in February 2016’ under each of the above.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA131 - Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years - HSC (SQSD) (NICE) 30/08 Note this guidance has been updated and replaced by NG245 - Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN), endorsed by the DoH in January 2025.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA134 - Infliximab for the treatment of adults with psoriasis - HSC (SQSD) (NICE) 31/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA136 - Structural Neuroimaging in first onset psychosis - HSC (SQSD) (NICE) 32/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA137 - Rituximab for the treatment of relapsed or refractory stage iii or Stage iv follicular Non-Hodgkin’s lymphoma - HSC (SQSD) (NICE) 56/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA138 - Corticosteroids for the treatment of chronic asthma in adults and children aged 12 years and over - HSC (SQSD) (NICE) 10/09 Note this guidance has been updated and replaced by NG245 - Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN), endorsed by the DoH in January 2025.

​National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA139 - Continuous Positive Airway Pressure (CPAP) for the treatment of Obstructive Sleep Apnoea/Hypopnoea Syndrome (OSAHS) - HSC (SQSD) (NICE) 57/08 - ‘Note this guidance has been partially updated by NICE Clinical Guideline NG202 - Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s, which was endorsed by the DoH in November 2021.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA140 - Infliximab for the treatment of ulcerative colitis - HSC (SQSD) (NICE) 01/09

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA141 - Abatacept for the treatment of rheumatoid arthritis

• This guidance has been replaced by NICE TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor, which was endorsed by DoH in November 2011

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA142 - Erythropoietin (alpha and beta) and darbepoetin for the treatment of cancer -treatment induced anaemia - HSC (SQSD) (NICE) 11/09

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA143 - Adalimumab, Atanercept and Infliximab for ankylosing spondylitis

• This guidance has been replaced by NICE TA383 - TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis, which was endorsed by the DoH in February 2016.

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA145 - Cetuximab for the treatment of head and neck cancer - HSC (SQSD) (NICE) 03/09

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA146 - Adalimumab for the treatment of psoriasis - HSC (SQSD) (NICE) 04/09

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA155 - Pegaptanib and Ranibizumab for age-related macular degeneration - HSC (SQSD) (NICE) 53/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA156 - Pregnancy - Routine antenatal Anti-D Prophylaxis for women who are Rhesus D negative - HSC (SQSD) (NICE) 54/08

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA159 - Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin - HSC (SQSD) (NICE) 16/09

National Institute for Health and Clinical Excellence (NICE) Technology Appraisal TA162 - Erlotinib for the treatment of non-small cell lung cancer

• This guidance has been replaced by NICE TA 374, Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy, which was endorsed by DoH in January 2016